The purpose of this Phase I, open-label, single sequence drug-drug interaction trial in human
immunodeficiency virus-type 1 infected patients is to investigate the potential interaction
between steady-state nevirapine (NVP) 200 mg b.i.d. (twice a day) and a single dose of 400 mg
TMC207 and to explore the pharmacokinetics (how the drug is absorbed into the bloodstream,
distributed in the body and eliminated from the body).